Comparison of staurosporine and four analogues: Their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells

British Journal of Cancer

Volumn 73, Issue 9, 1996, Pages 1063-1068

  Budworth, J ^a   Davies, R ^a   Malkhandi, J ^b   Gant, T W ^a   Ferry, D R ^b   Gescher, A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

CGP 41251; MCF 7 Adr cells; Multidrug resistance; Protein kinase C; Staurosporine

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 7 HYDROXYSTAUROSPORINE; GLYCOPROTEIN P; MIDOSTAURIN; RESERPINE; RHODAMINE 123; STAUROSPORINE; VINBLASTINE;

ARTICLE; BINDING SITE; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL;

EID: 0029988743     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.205     Document Type: Article

References (26)

1. AKINAGA S, GOMI K, MORIMOTO M, TAMAOKI T AND OKABE M. (1991). Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res., 51, 4888-4892.
2. BHAT UG, WINTER MA AND BECK WT. (1994). Reserpine/ yohimbine analogs increase mdr1 mRNA expression in a colon carcinoma cell line. Proc. Amer. Assoc. Cancer Res., 35, 2072.
3. CHAMBERS TC, ACAVOY EM, JACOBS JW AND EILON G. (1990). Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J. Biol. Chem., 265, 7679-7686.
4. CORNWALL MM AND SMITH DE. (1993). A signal transduction pathway for the activation of the mdr1 promotor involves the proto-oncogene c-raf kinase. J. Biol. Chem., 268, 15347-15350.
5. COURAGE C, BUDWORTH J AND GESCHER A. (1995). Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation. Br. J. Cancer, 71, 697-704.
6. DAVIES R, BUDWORTH J, RILEY J, SNOWDEN R, GESCHER A AND GANT TW. (1996). Transcriptional and post-transcriptional regulation of MDR 1 and 2 gene expression in two multidrug resistant subclones of the MCF-7/Adr brerast cancer cell line. Br. J. Cancer, (in press).
7. DAVIS PD, ELLIOTT L, HARRIS W, HURST SA, KEECH E, KUMAR H, LAWTON G, NIXON JS AND WILKINSON SE. (1992). Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. J. Med. Chem., 35, 994-1001.
8. EFFERTH T, LÖHTRKE H AND VOLM M. (1989). Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res., 9, 1633-1638.
9. FAIRCHILD CR, KAO-SHAN CS, WANG-PENG J, ROSEN N, ISRAEL MA, MALERA PW, COWAN KH AND GOLDSMITH ME. (1987). Isolation of amplified and overexpressed DNA sequences from adriamycin resistant human breast cancer cells. Cancer Res., 47, 5141-5148.
10. FERRY DR, RUSSELL MA AND CULLEN MH. (1992). P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is allosterically coupled to a vinca alkaloid-selective binding site. Biochem. Biophys. Res. Commun., 188, 440-445.
11. 3H]vinblastine binding to P-glycoprotein of MCF-7/Adr cells. Biochem. Pharmacol., 49, 1851-1861.
12. GEKELER V, BOER R, ISE W, SANDERS KH, SCHACHTELE C AND BECK J. (1995). The specific bisindolylmaleimide PKC inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. Biochem Biophys. Res. Commun., 206, 119-126.
13. HOFMANN J, WOLF A, SPITALER M, BÖCK G, LUDESCHER C AND GRUNICKE H. (1992). Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J. Cancer Res. Clin. Oncol., 118, 361-366.
14. MEYER T, REGENASS U, FABBRO D, ALTERI E, RÖSEL J, MÜLLER M, CARAVATTI G AND MATTER A. (1989). A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vitro antitumour activity. Int. J. Cancer, 43, 851-856.
15. MIYAMOTO K, INOKO K, WAKUSAWA S, KAJITA S, HASEGAWA T, TAKAGI K AND MASAO K. (1993). Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo. Cancer Res., 53, 1555-1559.
16. NEYFAKH AA. (1988). Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp. Cell Res., 174, 168-176.
17. O'BRIAN CA, FAN D, WARD NE, SEID C AND FIDLER IJ. (1989). Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells. FEBS Lett., 246, 78-82.
18. OMURA S, IWAI J, HIRANO A, NAGAKAWA A, AWAYA J, TSUCHIYA H, TAKAHASHI Y AND MASUMA R. (1977). A new alkaloid AM-2282 of Streptomyces origin; taxonomy, fermentation, isolation and preliminary characterization. J. Antibiotics, 30, 275-282.
19. PEARCE HL, SAFA R, AHMAD S, BACH NJ, WINTER MA, CIRAIN CM AND BECK WT. (1989). Essential features of the p-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate drug resistance. Proc. Natl Acad. Sci. USA, 86, 5128-5132.
20. POWIS G. (1992). Signalling targets for anticancer drug development. Trends Pharmacol. Sci., 12, 188-194.
21. SAMPSON E, WOLFF CL AND ABRAHAM I. (1993). Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Cancer Lett., 68, 7-14.
22. SATO W, YUSA K, NAITO M AND TSURUO T. (1990). Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem. Biophys. Res. Commun., 173, 1252-1257.
23. TAMAOKI T AND NAKANO H. (1990). Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology, 8, 732-735.
24. TOULLEC D, PIANETTI P, COSTE H, BELLEVERGUE P, GRANDPERRET T, AJAKANE M, BAUDET V, BOISSIN P, BOURSIER E, LORIOLLE F, DUHAMEL L, CHARON D AND KIRILOVSKY J. (1991). The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem., 266, 15771-15781.
25. UTZ I, HOFER S, REGENASS U, HILBE W, THALER W, GRUNICKE H AND HOFMANN J. (1994). The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int. J. Cancer, 57, 104-110.
26. WAKUSAWA S, INOKO K AND MITAMOTO K. (1993). Staurosporine derivatives reverse multidrug resistance without correlation with their protein kinase inhibitory activities. J. Antibiotics, 46, 335-337.